Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
not_yet_recruiting133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_4

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07187466
completedphase_3

Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease

NCT01520948
completednot_applicable

Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease

NCT00866710

Clinical Trials (3)

Showing 3 of 3 trials
NCT07187466Phase 4

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

Not Yet Recruiting
NCT01520948Phase 3

Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease

Completed
NCT00866710Not Applicable

Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease

Completed

All 3 trials loaded

Drug Details

Intervention Type
BEHAVIORAL
Total Trials
3